Estimands, Estimators and Sensitivity Analysis in Clinical Trials: Chapman & Hall/CRC Biostatistics Series
Autor Craig Mallinckrodt, Geert Molenberghs, Ilya Lipkovich, Bohdana Ratitchen Limba Engleză Hardback – 10 feb 2020
This book lays out a path toward bridging some of these gaps. It offers
A common language and unifying framework along with the technical details and practical guidance to help statisticians meet the challenges
A thorough treatment of intercurrent events (ICEs), i.e., postrandomization events that confound interpretation of outcomes and five strategies for ICEs in ICH E9 (R1)
Details on how estimands, integrated into a principled study development process, lay a foundation for coherent specification of trial design, conduct, and analysis needed to overcome the issues caused by ICEs:
A perspective on the role of the intention-to-treat principle
Examples and case studies from various areas
Example code in SAS and R
A connection with causal inference
Implications and methods for analysis of longitudinal trials with missing data
Together, the authors have offered the readers their ample expertise in clinical trial design and analysis, from an industrial and academic perspective.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 381.57 lei 43-57 zile | |
CRC Press – 13 dec 2021 | 381.57 lei 43-57 zile | |
Hardback (1) | 729.20 lei 22-36 zile | +20.63 lei 5-11 zile |
CRC Press – 10 feb 2020 | 729.20 lei 22-36 zile | +20.63 lei 5-11 zile |
Din seria Chapman & Hall/CRC Biostatistics Series
- 9% Preț: 801.31 lei
- 9% Preț: 643.31 lei
- 9% Preț: 643.04 lei
- Preț: 341.42 lei
- Preț: 311.41 lei
- 8% Preț: 376.64 lei
- Preț: 350.65 lei
- 5% Preț: 657.06 lei
- Preț: 356.63 lei
- Preț: 348.37 lei
- Preț: 311.41 lei
- Preț: 354.48 lei
- Preț: 359.03 lei
- Preț: 342.89 lei
- Preț: 354.77 lei
- Preț: 386.62 lei
- 9% Preț: 641.52 lei
- 5% Preț: 331.01 lei
- Preț: 288.80 lei
- 5% Preț: 669.54 lei
- Preț: 362.00 lei
- 9% Preț: 731.99 lei
- 9% Preț: 644.57 lei
- Preț: 356.63 lei
- 9% Preț: 833.28 lei
- 9% Preț: 608.32 lei
- Preț: 357.22 lei
- 9% Preț: 594.30 lei
- 9% Preț: 940.38 lei
- 18% Preț: 775.13 lei
- 18% Preț: 692.28 lei
- 18% Preț: 1695.18 lei
- 26% Preț: 873.78 lei
- 18% Preț: 769.71 lei
- 25% Preț: 824.34 lei
- 15% Preț: 664.42 lei
- 25% Preț: 556.71 lei
- 26% Preț: 624.87 lei
- 18% Preț: 770.45 lei
- 25% Preț: 776.86 lei
- 25% Preț: 627.32 lei
- 18% Preț: 1102.17 lei
- 25% Preț: 886.18 lei
- 25% Preț: 525.99 lei
Preț: 729.20 lei
Preț vechi: 801.32 lei
-9% Nou
Puncte Express: 1094
Preț estimativ în valută:
139.55€ • 144.96$ • 115.92£
139.55€ • 144.96$ • 115.92£
Carte disponibilă
Livrare economică 13-27 ianuarie 25
Livrare express 27 decembrie 24 - 02 ianuarie 25 pentru 30.62 lei
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781138592506
ISBN-10: 1138592501
Pagini: 344
Ilustrații: 36 Tables, black and white; 20 Illustrations, black and white
Dimensiuni: 156 x 234 x 25 mm
Greutate: 0.45 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series
ISBN-10: 1138592501
Pagini: 344
Ilustrații: 36 Tables, black and white; 20 Illustrations, black and white
Dimensiuni: 156 x 234 x 25 mm
Greutate: 0.45 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series
Cuprins
Section I Setting the Stage 1. Introduction 2. Why Are Estimands Important? Section II Estimands 3. Estimands and How to Define Them 4. Strategies for Dealing with Intercurrent Events 5. Examples from Actual Clinical Trials in Choosing and Specifying Estimands 6. Causal Inference and Estimands 7. Putting the Principles into Practice Section III Estimators and Sensitivity 8. Overview of Estimators 9. Modeling Considerations 10. Overview of Analyses for Composite Intercurrent Event Strategies 11. Overview of Analyses for Hypothetical Intercurrent Event Strategies 12. Overview of Analyses for Principal Stratification Intercurrent Event Strategies 13. Overview of Analyses for While-on-Treatment Intercurrent Event Strategies 14. Overview of Analyses for Treatment Policy Intercurrent Event Strategies 15. Missing Data 16. Sensitivity Analyses Section IV Technical Details on Selected Analyses 17. Example Data 18. Direct Maximum Likelihood 19. Multiple Imputation 20. Inverse Probability Weighted Generalized Estimated Equations 21. Doubly Robust Methods 22. Reference-Based Imputation 23. Delta Adjustment 24. Overview of Principal Stratification Methods Section V Case Studies: Detailed Analytic Examples 25. Analytic Case Study of Depression Clinical Trials 26. Analytic Case Study Based on the ACTG 175 HIV Trial
Recenzii
"The purpose of this book, which is to promote an integrated understanding of key concepts throughout the drug development process through an example-based approach, is certainly achieved. It is the holistic approach to planning the analysis and the focus on practical implementation that distinguishes this text from others... Overall, I enjoyed reading this book, which is a holistic and complete work and will be useful for researchers in the medical statistics area."
- Taras Lukashiv, ISCB News, July 2020
- Taras Lukashiv, ISCB News, July 2020
Notă biografică
Geert Molenberghs is Professor of Biostatistics (Hasselt University, KULeuven. He works on surrogate endpoints, longitudinal and incomplete data, was Editor for Applied Statistics, Biometrics, Biostatistics, Wiley Probability & Statistics, and Wiley StatsRef and is Executive Editor of Biometrics. He was President of the International Biometric Society, is Fellow of the American Statistical Association, and received the Guy Medal in Bronze from the Royal Statistical Society. He has held visiting positions at the Harvard School of Public Health.
Ilya Lipkovich is a Sr. Research Advisor at Eli Lilly and Company. He is a Fellow of the American Statistical Association and published on subgroup identification in clinical data, analysis with missing data, and causal inference. He is a frequent presenter at conferences, a co-developer of subgroup identification methods, and a co-author of the book "Analyzing Longitudinal Clinical Trial Data. A Practical Guide."
Bohdana Ratitch is a Principal Research Scientist at Eli Lilly and Company. Bohdana has contributed to research and practical applications of methodologies for causal inference and missing data in clinical trials through active participation in a pharma industry working group, numerous publications, presentations, and co-authoring the book "Clinical Trials with Missing Data: A Guide for Practitioners".
Craig Mallinckrodt holds the rank of Distinguished Biostatistician at Biogen in Cambridge MA. He has extensive experience in all phases of clinical research. His methodology research focuses on longitudinal and incomplete data. He is Fellow of the American Statistical Association, has led several industry working groups on missing and longitudinal data, and received the Royal Statistical Society’s award for outstanding contribution to the pharmaceutical industry.
Ilya Lipkovich is a Sr. Research Advisor at Eli Lilly and Company. He is a Fellow of the American Statistical Association and published on subgroup identification in clinical data, analysis with missing data, and causal inference. He is a frequent presenter at conferences, a co-developer of subgroup identification methods, and a co-author of the book "Analyzing Longitudinal Clinical Trial Data. A Practical Guide."
Bohdana Ratitch is a Principal Research Scientist at Eli Lilly and Company. Bohdana has contributed to research and practical applications of methodologies for causal inference and missing data in clinical trials through active participation in a pharma industry working group, numerous publications, presentations, and co-authoring the book "Clinical Trials with Missing Data: A Guide for Practitioners".
Craig Mallinckrodt holds the rank of Distinguished Biostatistician at Biogen in Cambridge MA. He has extensive experience in all phases of clinical research. His methodology research focuses on longitudinal and incomplete data. He is Fellow of the American Statistical Association, has led several industry working groups on missing and longitudinal data, and received the Royal Statistical Society’s award for outstanding contribution to the pharmaceutical industry.
Descriere
This book will use the new guidance as a framework for developing and implementing comprehensive analysis plans for clinical trials that support the development and approval of medical interventions.